However, the prolonged exposure to unopposed oestrogens stimulates the growth of endometrium, thus increasing the risk Department of Obstetrics and Gynecology, Shimane Medical of endometrial hyperplasia. An increasing number of women University, Japan are receiving HRT with oestrogens plus added progestogens 1 To whom correspondence should be addressed to prevent endometrial hyperplasia and neoplasia (Ettinger et al., 1998) . Recently, it was reported (Hulley et al., 1998) To assess the safety and efficacy of oestriol in relieving that treatment with oral conjugated equine oestrogen plus post-menopausal symptoms 53 post-menopausal Japanese medroxyprogesterone acetate did not reduce the overall rate women with climacteric symptoms, 27 with natural menoof coronary heart disease events in post-menopausal women pause (group I) and 26 with surgically induced menopause with established coronary disease. However, the debate on this (group II), received oral oestriol, 2 mg daily for 12 months.
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regimen remains controversial regarding the development of Clinical parameters including Kupperman index (KI) and breast cancer (Bergkvist et al., 1989; Colditz et al., 1995) . the degree of satisfaction with symptomatic relief; serum
The benefits of HRT must always be weighed against their risks.
concentrations of oestradiol, FSH and LH; serum lipids;
Oestriol, a weak oestrogen, has been successfully used in blood pressure; bone mineral density, serum calcium (Ca), treating post-menopausal women in several countries for more alkaline phosphatase (ALP), and urinary Ca were comthan 30 years, and is considered to lack the potential risks of pared between the two groups. Oestriol improved KI in systemic oestrogen therapy (Esposito, 1991) . Oestriol seems groups I and II by 49 and 80% respectively. Satisfaction to present a logical alternative to standard oestradiol or with treatment was 85% in group I and 93% in group II.
other conjugated oestrogens used as HRT for women in the For both parameters, values were significantly different climacteric, and presents advantages to those at risk for between groups I and II (P < 0.05 for both). Serum endometrial cancer (Marslew et al., 1992) . Oestriol succinate concentrations of oestradiol, FSH and LH changed in group may have less thrombotic potential than synthetic oestrogens I versus group II 6 months after initiation. A significant (Toy et al., 1978) . Of the three human oestrogens, oestriol is decrease in serum ALP and Ca/Cr was observed in group the only one to lack mitogenic activity, while it protects I at 6 months. Except for serum triglycerides, oestriol had the reproductive organs by means of its competition with no significant effect on lipids. Systolic and diastolic blood endogenous oestrogens for the receptor (Lemon, 1975) . Howpressures were significantly decreased in group I at 3 ever, it is still a subject of debate (Weiderpass et al., 1999) .
months versus baseline. Slight vaginal bleeding occurred
There are relatively few publications on the effects of oestriol in 14.3% of group I. Histological evaluation of the endometon the symptoms of the climacteric (Tzingounis et al., 1978 , rium in all women of group I and ultrasound assessment 1980; Schneider, 1982; Kopera, 1983; Lauritzen, 1987 ;Introduction A total of 53 post-menopausal women (aged 40-62 years) with
The benefits of hormone replacement therapy (HRT) are well climacteric symptoms were included in this study. Each subject gave established for the relief of climacteric symptoms in posther written informed consent for participation. The study was approved by our hospital ethics committee. 'Post-menopausal' was defined as menopausal women as well as for the prevention of osteopor-amenorrhoea that had persisted for ജ 6 months. All patients had The severity of the climacteric symptoms was evaluated according
Serum HDL-C (mg/dl) 60.6 Ϯ 13.9 62.2 Ϯ 15.6
to the Kupperman index (KI) (Kupperman et al., 1959) using endometrial biopsy, and the presence of breast tumours by ultrasound before and after treatment. Endometrial biopsies were obtained with a curette without local anaesthesia. These specimens Determination of lipid profiles were fixed in neutral formalin, embedded in paraffin wax and sectioned Total cholesterol (TC), triglycerides (TG) and high density lipoprotein at several levels. All biopsies were examined by a pathologist for cholesterol (HDL-C) were measured enzymatically with an automatic signs of hormonal effects and atypia. Blood samples were collected multi-purpose analyser (TBA 200 FR, Toshiba Medical Products, from the subjects early in the morning after an overnight fast. Sera Tokyo, Japan). Total cholesterol was measured enzymatically using were stored at -30°C. To minimize variation, each subject's sample Determiner LTC-S (Kyowa Medex, Tokyo, Japan) (intra-and interwas analysed at the same time. Pretreatment biometric data, reproassay CV, 0.96 and 0.94% respectively). Triglycerides were measured enzymatically using Autosera STGN (Daiichi Chemical, Tokyo Japan) ductive history, endogenous sex hormones, estimates of calcium (intra-and inter-assay CV of 0.66 and 1.02% respectively). The metabolism, bone mineral density, estimates of lipid metabolism, and concentration of HDL-C was measured by a direct method (Nauck the blood pressure at the outset of the study are shown in Table I . et al., 1996) with the use of Determiner L HDL-C (Kyowa Medex Except for age and time since occurrence of natural menopause or Tokyo, Japan) (intra-and inter-assay CV, 1.12 and 1.59% respectively). of hysterectomy with bilateral oophorectomy, the two groups showed
The concentration of low density lipoprotein cholesterol (LDL-C) no significant differences.
was calculated from the formula TC -TG/5 -HDL-C (Friedewald et al., 1972) . Assay of serum concentrations of sex hormones Serum concentrations of oestradiol, FSH and LH were measured with Bone mineral density and biochemical markers of bone turnover commercially available kits before the initiation of the study and Bone mineral density (BMD) was assessed by use of the microdensitorepeated every 6 months. Samples were obtained approximately 6 h metry (MD) method (Inoue et al., 1983) . The BMD of the second after the intake of medication. Oestradiol concentrations were determetacarpal bone of each subject was measured by X-ray using the mined by radioimmunoassay using the Coat-A-Count oestradiol kit MD method before and after treatment. An X-ray of the hand was (Nippon DPC, Chiba, Japan), whose intra-assay and inter-assay also taken with a reference aluminium step-wedge. In the MD method, coefficients of variation (CV) were Ͻ7 and 6.2% respectively. The three indices, such as the metacarpal index (MCI), the index of the reference method has 10.0% cross-reactivity with oestrone and 0.32% densities of bone cortex and bone marrow (GSmin) and the index of with oestriol. FSH and LH were measured by radioimmunoassay bone density per unit length (sigma GS/D), were calculated by using the SPAC-S FSH kit and SPAC-S LH kit (Daiichi Radioisotope computer analysis of the X-ray of each hand. In addition, serum Laboratory, Tokyo, Japan), whose intra-assay and inter-assay CV concentrations of calcium (Ca), inorganic phosphate (Pi), alkaline phosphatase (ALP), and urinary Ca were measured to evaluate bone were 4.8 and 5.3%, and Ͻ8 and 4% respectively. oestradiol values prior to study entry and at the start of this changes in parameters after the initiation of oestriol. A level of study: group I, 13.5 Ϯ 9.0 and 13.9 Ϯ 11.7 pg/ml respectively; P Ͻ 0.05 was considered statistically significant. group II, 12.0 Ϯ 2.9 and 13.1 Ϯ 5.4 pg/ml respectively). Statistical analysis of mean oestradiol values (21.8 Ϯ Results 12.2 pg/ml) at the 6 months of treatment showed a significant increase (P Ͻ 0.01) in group I as compared with mean Three patients in group I reported slightly unexpected vaginal bleeding. The bleeding stopped of its own accord despite pretreatment values. This effect continued until the end of the 12 month treatment period (17.1 Ϯ 7.4 pg/ml). No statistically continuation of medication. Endometrial biopsy specimens taken during the bleeding incidences showed an atrophic significant changes in serum oestradiol were observed in group II during treatment. Mean serum concentrations of FSH endometrium without malignancy in one patient and weakly proliferative endometrium without malignancy in two patients.
(66.4 Ϯ 32.2 mIU/ml) and LH (23.7 Ϯ 13.0 mIU/ml) showed a significant decrease (P Ͻ 0.01) 6 months after starting Furthermore, histological evaluation of the endometrium following 12 months of oestriol treatment found no atypical treatment in group I as compared with pretreatment values. This decrease continued until the end of the 12 months of endometrium in all patients of group I including atrophic endometrium in 23 patients (85.2%) and weakly proliferative treatment (68.6 Ϯ 30.5 mIU/ml in FSH and 25.4 Ϯ 11.0 mIU/ml in LH). In group II, the mean FSH (59.6 Ϯ endometrium in four women (14.8%). Ultrasound assessment of the breasts following 12 months of treatment found no 15.7 mIU/ml) and mean LH (24.5 Ϯ 9.9 mIU/ml) at 12 months after the start of treatment showed a significant decrease as tumour in all women of both groups. Other adverse effects were observed in four patients: epigastralgia in three patients compared with pretreatment values (P Ͻ 0.01 and P Ͻ 0.05 respectively, while no statistically significant changes were and mastodynia in one patient. However, no patient discontinued treatment due to side-effects. observed in both serum FSH and LH concentrations 6 months after starting treatment. The menopausal index of Kupperman (KI) was employed to estimate subjective improvement. Both total KI scores in No statistically significant changes were seen in either group with regard to the markers of bone mineral density (MCI, group I and group II prior to study entry (17.8 Ϯ 6.7 and 17.6 Ϯ 7.3 points respectively) were significantly increased at GSmin and sigma GS/D). Concerning the biochemical markers of bone turnover, during the 12 months of treatment, no the start of this study. Only one patient in group I exhibited severe post-menopausal symptoms at the outset (KI Ͼ35). The statistically significant changes were observed in any such markers in group II, and in the serum concentration of Ca in average scores and the percentage change in KI from baseline before and after treatment are shown for each group in Figure 1 . group I. In group I, the mean ALP (107.0 Ϯ 60.6 IU/l) and iP values (3.29 Ϯ 0.51 mg/dl) at the end of treatment showed At the end of the first month, the index was significantly reduced in both groups: 37.5% in group I and 28.8% in group a significant decrease (P Ͻ 0.05) as compared with pretreatment values respectively. Statistical analysis of mean urinary Ca/Cr II. Group I showed a gradual reduction in the KI over the 3 months after initiating oestriol, with a 49.8% reduction after values (0.21 Ϯ 0.10) at 6 months of therapy showed a significant decrease (P Ͻ 0.01) in group I as compared with 3 months of treatment. However, the continuation of treatment did not seem to induce any further substantial decreases in pretreatment values. This decrease continued until the end of the 12 month study (0.19 Ϯ 0.10 pg/ml). This value after 12 this index (8.6 Ϯ 7.8 points and 49.2 Ϯ 47.0% of mean KI and reduction rate respectively at the end of treatment). Group months of treatment differed significantly from the value in group II (0.29 Ϯ 0.10) (Figure 4 ). II showed a significant reduction in KI 3 months after initiating oestriol treatment, with a 56.8% reduction observed at No statistically significant changes were observed during treatment in serum concentrations of TG, HDL-C and LDL-C 3 months. Significant substantial reductions in this index were also observed over the next 9 months (3.6 Ϯ 3.1 points and in either group. In group I, the mean TC (194.0 Ϯ 
Discussion
Most studies on the treatment of complaints associated with the climacteric have utilized oestradiol or conjugated oestrogens as therapy, with relatively few reports on the effect of oestriol (Tzingounis et al., 1978 (Tzingounis et al., , 1980 Schneider, 1982; Kopera, 1983; Lauritzen, 1987; Bottiglione et al., 1995) . The use of oral oestriol as HRT remains controversial. For instance, a previous study reported that oestriol succinate administered at a dose of 2-4 mg/day orally for 1 year had little beneficial effect on climacteric symptoms, as shown by KI values (Grasso et al., 1982) . Oral oestriol is rapidly inactivated by the liver to its glucuronide derivative, so that only 1-2% of the total dose administered enters the circulation in a bioactive form (Schiff et al., 1978; Heimer, 1987) . The massive inactivation is influenced by the time of administration as well as by food intake, such that the circulating concentration of this hormone is difficult to maintain within the treatment range (Heimer, given in divided amounts have been utilized. Heimer and Englund (Heimer and Englund, 1984) administered 6 and 12 mg of oestriol. A dose of 8 mg oestriol reportedly relieves hot flushes (Schneider, 1982) . 37.1 mg/dl) at the end of treatment showed a significant Nevertheless, such high doses of oestriol produce the same (P Ͻ 0.05) decrease as compared with pretreatment values, late responses, and the same endometrial and metabolic effects, whereas no statistically significant changes were observed in as do the other oestrogens, because the nuclear permanence group II ( Figure 5 ).
of oestriol receptors was double. Such high doses also induced Changes in blood pressure before and during treatment are side-effects such as nausea and mastalgia. The administration shown in Figure 6 . No statistically significant changes in blood of oestriol by the vaginal route has been tried (Keller et al., pressure were observed in group II during the 12 months of 1981; Bottiglione et al., 1995; Melis et al., 1996) . It was treatment. However, in group I, the mean systolic pressure concluded that intra-vaginal oestriol is rapidly absorbed and (114.2 Ϯ 15.2 mm Hg) and diastolic pressure (71.7 Ϯ is suitable for local and systemic oestrogen replacement 10.8 mm Hg) each showed a significant decrease (P Ͻ 0.05) at 3 months as compared with pretreatment values respectively. therapy, and that it was more effective than the oral regimen 
(d-d) and group II (s-s). (d-d) and group II (s-s). Mean values are shown, SE is
Mean values are shown, SE is indicated by error bars. *P Ͻ 0.05; indicated by error bars. *P Ͻ 0.05; **P Ͻ 0.01 versus respective **P Ͻ 0.01 versus respective pretreatment values; †P Ͻ 0.05 pretreatment values.
versus group II at that time. (Keller et al., 1981) . With 1 mg daily transvaginal oestriol the reduction at 3 months). The continuation of treatment for 12 KI significantly decreased by~50% after 2 weeks; KI scores months was associated with a further significant decrease in were reduced by~70% by the end of treatment (Bottiglione the index (3.6 Ϯ 3.1 points and 80.4 Ϯ 20.2% of mean KI et al., 1995) . However, long term therapy using the intraand reduction rate respectively). This value at 12 months was vaginal route for oestriol administration has not received significantly lower than that reported in the women who had patient acceptance in Japan.
undergone natural menopause. In addition, the satisfaction The present study showed that oestriol at a dose of 2 mg/day with hormonal therapy was significantly higher in the women significantly relieved climacteric symptoms in postmenstrual with surgically induced menopause than in those who had women. In those who had undergone natural menopause, the undergone natural menopause. The younger age and shorter KI was significantly reduced by 37.5% at 1 month. The index time since menopause induced by hysterectomy and oophorecthen gradually declined over 3 months of treatment (49.8% tomy may perhaps explain the difference. Also, in women reduction at 3 months). However, the continuation of treatment with early surgical menopause, treatment compliance may be did not induce any further marked decrease in the KI, which easier. It is also possible that the same dose of oestriol has a is similar to earlier findings (Tzingounis et al., 1980) . However, stronger effect in women with surgically induced menopause. in women with surgically induced menopause, the KI showed
In the present study, a significant increase in serum oestradiol a significant reduction at 3 months of treatment (56.8%
concentration was observed at 6 months of the oestriol treatment in women of the natural menopause group. This serum oestradiol elevation continued until the end of the 12 month period of treatment. However, this oestradiol increase was not seen in women who had oophorectomy. Although these elevated oestradiol concentrations might be accounted for by some residual ovarian activity, no statistically significant changes in serum oestradiol were observed in the natural menopause group during treatment by placebo prior to study entry. We also previously reported that the serum concentration of oestradiol increased transiently to be Ͼ100 pg/ml in four women who were treated with oestriol within 5 years of the menopause (Okada et al., 1995) . Therefore, it is considered that the administration of oestriol may have stimulated ovarian granulosa cells directly and/or indirectly to produce oestradiol, since oestriol itself cannot be converted to oestradiol. However, a detailed discussion of the oestradiol changes observed was not possible, since serum oestriol concentrations were not measured. Furthermore, the significant decreases in serum FSH and LH observed at the end of the 12 month study are more FSH and LH) rather than a reduction due to oestradiol production by the ovary leading to negative feedback, as judged reported that the serum Ca is significantly increased in postmenopausal women as compared with that in premenopausal from the previous report of the lowered serum concentrations of FSH and LH in normal ovulatory women (Vahapassi and women, and is reduced to the premenopausal value by HRT (Leino et al., 1994) . Although oestriol might be clinically Adlercreutz, 1975) , although it is well known that significant decreases in serum FSH and LH result from the negative feedeffective in maintaining normal bone metabolism in women with natural menopause from the current results, assessing back phenomenon produced by the elevation of oestradiol as a physiological phenomenon.
biochemical markers of bone turnover (serum total and bonespecific ALP, serum C-terminal propeptide of type I collagen Osteoporosis is common in post-menopausal women who have such risk factors as deficiencies of oestrogen and calcium.
and serum osteocalcin as bone formation markers, and urinary cross-linked N-telopeptide of type I collagen as bone resorption Oestrogen administration inhibits bone resorption, and can thus prevent further bone loss in such high-risk women index) must be more useful in the evaluation of oestriol treatment (Garnero et al., 1996) . (Lindsay and Cosman, 1990) . Oestrogens suppress bone resorption at the time of accelerated bone turnover in the early stage
In general, oestrogen reduces TC and LDL-C, while increasing HDL-C (Knopp, 1988) . However, no distinct effects of after menopause and in elderly women, and suppress the reduction of bone mass, resulting in either the maintenance oestriol on lipids were observed in the menopausal women studied. Only serum TC showed a significant decrease in the of, or an increase in, BMD (Lindsay and Tohme, 1990) . However, oestriol therapy does not prevent post-menopausal naturally menopausal women. It is well known that several types of oestrogens are used clinically for HRT and their osteoporosis, as revealed by evaluating the BMD of the lumbar spine using quantitative computed tomography (Yang et al., oestrogenic effects on the biological system may vary based on their chemical structures. Hence the outcome of the HRT 1995). However, its effect on BMD has not been fully evaluated. The combined administration of intra-vaginal oesmay depend on the type of oestrogen used (The ESHRE Capri Workshop, 1998) . In this regard, as compared to oestradiol, triol and of a nasal spray containing salmon calcitonin to postmenopausal women improved the neurovegetative symptoms oestriol is a weak oestrogen that is known to have minimal uterotrophic effects (Anderson et al., 1975) , and hence lacks and prevented a decrease in BMD (Melis et al., 1996) . The rate of increase in the BMD of the lumbar vertebrae in the the deleterious effects seen with oestradiol. On the other hand, oestriol may not be as effective in protecting post-menopausal post-menopausal women administered orally 2 mg/day oestriol daily was recently evaluated. HRT with oestriol is effective in women against cardiovascular disease as it has no antimitogenic effects on vascular smooth muscle cell growth, which plays a treating involutional osteoporosis, the bones of elderly women also maintain responsiveness to oestriol (Nishibe et al., 1998) .
key role in vascular remodelling and neo-intima formation. Indeed, the same reason may be responsible for the lack of One study (Minaguchi et al., 1996) has presented similar findings, that oestriol prevented post-menopausal bone loss; it cardioprotective effect of conjugated equine oestrogens, as they contain less potent oestrogens such as oestrone and concluded, based on the placebo results, that oestriol may be safe and efficacious.
oestriol (ESHRE Capri Workshop, 1998) . Similarly, the effects on bone density may vary. No significant change in BMD was observed in the present study. This differing result may be related to the methods of With regard to the potential mechanisms for the lack of effects on lipid, the binding affinity of oestriol to alpha or beta measurement. i.e. the BMD was measured at the middle of the metacarpal bone II with a densitometer on X-rays of the oestrogen receptor (ER), its antioxidant potential as well as antagonistic effects on oestradiol mediated effects may be hands taken from the dorsal along an aluminium step-wedge. Although this method shows good reproducibility, the change considered. The effects of oestrogen and oestrogen agonists can be mediated by ER. Recent discovery of a new ER (Kuiper in BMD of the metacarpal bone II as measured in this manner may be slower to show a change than when one evaluates the et al., 1996) has led to further questions regarding separate roles for these two receptors, termed ERα and ERβ. In the rat lumbar vertebrae (L2-L4) using dual-energy X-ray absorptiometry. However, it is reassuring that bone density did not the highest expressions of ERα occur in the testes, pituitary gland, uterus, kidneys and adrenal glands; highest expressions decline over the 12 months.
In the biochemical parameters of bone metabolism we of ERβ occur in the ovary and the prostate . Some data suggest that oestradiol activates transcription examined, there were no significant decreases in all parameters in surgically induced menopausal women during treatment, with ERα and inhibits at ERβ, whereas tamoxifen, raloxifene, and ICI 164 384 activate transcription with ERβ (Paech et al., while there were significant decreases in urinary Ca/Cr in natural menopausal women at 6 months and again at the end 1997). Further work in the field of molecular and genetic endocrinology has shed more light on the complex subject of of 12 months administration. This decrease in markers of bone breakdown in the naturally menopausal women could be anti-oestrogenic agonist and antagonist modes of action. It has been proposed (Petersen et al., 1998) that ERβ2 should be related to the higher oestradiol concentrations due to persistent ovarian activity and/or stimulating effect of the oestriol on considered in addition to ERβ1 and ERα when describing the effects of oestrogen, oestrogen agonists/antagonists, or ovary directly and/or indirectly. However, there was no significant change in serum Ca during treatment in the naturally environmental oestrogens. ERβ2 bound oestradiol with a lower affinity than either ERα or ERβ1. The binding of ERβ2 menopausal women. This finding resembles that of a report in which no decrease in serum Ca was seen in post-menopausal was selective in that cortisol, testosterone, aldosterone, and progesterone among other agents did not compete for oestradiol women (Nishibe et al., 1998) . However, it has also been binding. However, a variety of known oestrogenic agents, oestriol. The present study suggests that oestriol may be a safe and effective alternative for the relief of climacteric symptoms including physiological oestrogens (oestrone and oestriol), plant and environmental oestrogens (genistein, coumestrol, in post-menopausal women who reject, or who have contraindications, to conventional HRT with oestradiol or conjugated bisphenol A, methoxychlor), and pharmocological agents (tamoxifen, α-hydroxytamoxifen) effectively competed for oestrogens. Few side-effects were observed, and endometrial examination revealed no abnormalities. All patients completed oestradiol binding to both ERβ1 and ERβ2. Thus, although it has been demonstrated that ERβ2 possesses altered binding of the 12-month study. About 90% were satisfied with the results at the end of hormonal treatment. The beneficial biochemical oestradiol, and in addition, some ligands exhibit potent agonism of ERβ2 while antagonizing ERδ and ERβ1 (Petersen et al., effects of oestriol were marked in the natural menopausal women. It is possible that these effects are related to the 1998), it is not yet known how ERβ1 or ERβ2 respond to oestriol. Further investigation may increase the understanding stimulation of oestradiol production from ovaries which may retain some partial function activity. of the mechanisms of action of medically important oestrogenic compounds.
However, a recent paper (van Haaften et al., 1997) showed that similar signs of oestrogen stimulation of the endometrium Post-menopausal women have an increased incidence of cardiovascular disease; it is well known that HRT with oestrawere seen following oestradiol and oestriol medication in the histological studies. Furthermore, another study (Weiderpass diol or conjugated oestrogens reduces this risk (Dubey et al., 1998; Modena et al., 1998) . Both the systolic and diastolic et al., 1999) warned that close surveillance of patients is needed and addition of a progestagen should be considered, blood pressure are higher in post-menopausal women than in men of same age or in premenopausal women, suggesting that since oral use of oestriol 1-2 mg daily increased the relative risk of endometrial cancer and endometrial hyperplasia: the oestrogen deficiency may influence the age-related increase in blood pressure (Bairey et al., 1998; Mercuro et al., 1998) .
odds ratios for at least five years of use compared with never use were 3.0 and 8.3 respectively. Therefore, the final results Although it has been reported that the administration of oestradiol for relatively short periods (4-12 months) has no must be regarded with caution until confirmed on the basis of a double-blind, placebo-controlled trial in a large number effect on blood pressure (Serup et al., 1981; Christiansen et al., 1982; Blum et al., 1986) , in recent studies, the administration of of patients.
In conclusion, the efficacy and safety of oestriol in relieving oestradiol significantly reduced the 24-h systolic and diastolic blood pressures (Danser et al., 1998) . Concentrations of climacteric symptoms was investigated in Japanese women with natural menopause and with surgically induced menoprorenin and renin in women who received oestrogen were significantly lower than those in women without oestrogen pause. Although no distinct effects of oestriol on lipids and bone were observed, the effects of oestriol on the parameters administration (Danser et al., 1998) . HRT using oestradiol and progesterone may protect post-menopausal women against studied in the two groups of post-menopausal women were not identical. It was demonstrated that the hormonal effects of cardiovascular disease by inhibiting the growth of cardiac fibroblasts and of cardiac remodelling (Dubey et al., 1998) .
oestriol were stronger in women with natural menopause, while the relieving effects for climacteric symptoms were Nevertheless, the effect of oestriol on cardiac risk factors is somewhat equivocal. Oestriol does not seem to affect stronger in women with surgically induced menopause. However, the overall effects in both groups appear to be safe hypertension (Erkkola et al., 1978; Head, 1998) . However, in the present study, both the systolic and diastolic blood pressures and effective in relieving menopausal symptoms. In postmenopausal women who do not need medication for osteoporin the naturally menopausal women showed a significant decrease 3 months after starting treatment as compared with osis or coronary artery disease, oestriol may serve as a good choice for HRT to protect against other climacteric symptoms. mean pretreatment values. The reason for these results is not known, and further investigation in a larger number of patients is indicated. The administration of oestriol may stimulate the References ovarian granulosa cells directly and/or indirectly, stimulating It is well known that there is a marked placebo response in Bergkvist, L., Adami, H-O., Persson, I. et al. (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N. Engl. J. Med., 321,  terms of improvement of hot flushes and of KI (Saletu et al., (293) (294) (295) (296) (297) 1995). Furthermore, the reduction of climacteric symptoms Blum, M., Assa, S., Bacalu, B. et al. (1986) The influence of short-term could still be an effect of time since the menopause. However, estrogen replacement therapy (ERT) on the blood pressure and daily urinary catecholamine excretion in a small group of post-menopausal women. Eur.
in this study the Ca tablets as placebo were given at the start J. Obstet. Gynecol. Reprod. Biol., 23, [195] [196] [197] [198] [199] of the preliminary study when the symptoms would not have Bottiglione, F., Volpe, A., Esposito, G. et al. (1995) were considered to be attributed to the administration of
